New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2014
10:25 EDTDRRX, DRRX, PCRX, PCRXSummer Street's chief scientific officer holds analyst/industry conference call
Chief Scientific Officer Classen discusses Durect's (DRRX) Posidur for post-operative pain, its safety and whether it could be disruptive to Pacira Pharmaceuticals (PCRX) on an Analyst/Industry conference call to be held on January 8 at 11 am.
News For DRRX;PCRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 24, 2015
08:10 EDTDRRXDURECT likely to announce partnership soon, says Cantor
Subscribe for More Information
June 23, 2015
08:05 EDTDRRXDurect to conduct new POSIDUR Phase 3 clinical trial
Durect says based on feedback from the FDA, it plans to conduct a new POSIDUR, or SABER-Bupivacaine, Phase 3 clinical trial consisting of approximately 300 patients undergoing laparoscopic cholecystectomy surgery. DURECT anticipates beginning the trial in the fall of 2015 and expects that it will take approximately one year to complete enrollment. The study will be a randomized, parallel-group, double-blind, placebo-controlled, multicenter trial of POSIDUR in patients undergoing laparoscopic cholecystectomy. The objective of the study will be to evaluate the safety and efficacy of POSIDUR for the management of postoperative pain.
June 19, 2015
10:00 EDTPCRXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:49 EDTPCRXPacira initiated with a Market Perform at Leerink
Target $86.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use